A new review in Life Analysis shows how programmable DNA nanostructures overcome long-standing limits of electrochemiluminescence (ECL) biosensing. By controlling probe spacing, interfacial orientation and nanoscale confinement in one-, two- and three-dimensional architectures, DNA scaffolds boost sensitivity, stability and reproducibility. Combined with enzyme-free amplification circuits, DNA walkers and CRISPR-Cas modules, these platforms detect pathogen nucleic acids, microRNAs, proteins and intracellular markers.
Electrochemiluminescence (ECL) biosensing is a highly sensitive analytical technique that integrates electrochemical triggering with optical readout. Optimization of its performance involves not only the luminescent reaction system itself, but also multiple dimensions including interfacial molecular arrangement, signal transduction efficiency, and amplification mode design. A recent review published in Life Analysis systematically sorts out the latest research advances in DNA nanostructure-based ECL biosensors, with a focus on the core role of DNA nanostructures in precise interfacial engineering and programmable signal amplification.
By modulating interfacial ordering, donor–acceptor distance and nanoconfinement effects, DNA nanostructures effectively overcome the drawbacks of conventional ECL systems such as insufficient electron transfer efficiency, random probe orientation and limited single-mode amplification, making up for the performance bottlenecks that cannot be resolved by routine surface modification approaches. With the continuous progress of DNA self-assembly technologies and nucleic acid amplification strategies, this class of sensing platforms has achieved highly specific detection of diverse targets covering nucleic acids, proteins, small molecules and intracellular biomarkers. The review establishes a unified structure–activity relationship analytical framework, compares the performance differences of DNA nanostructures across different dimensions, summarizes the applicable scenarios of various signal amplification strategies, and objectively identifies the major challenges faced by the field in biological stability, scalable fabrication and clinical translation.
Key highlights include:
Structural programmability: DNA nanostructures with designable 1D, 2D and 3D architectures enable precise regulation of interfacial ordering, donor-acceptor distance and nanoconfinement effects in ECL systems.
Signal amplification: Integration of DNA nanostructures with HCR, CHA, RCA and DNA walker strategies achieves cascade signal enhancement for ultrasensitive biomarker detection.
Functional diversification: DNAzymes, logic circuits and CRISPR-Cas cascades are incorporated as functional modules to improve detection specificity and expand intelligent sensing capabilities.
The review further highlights that machine-learning-assisted DNA nanoengineering and point-of-care device integration will accelerate the clinical translation of ECL biosensing platforms.
This work outlines the overall landscape of DNA nanostructure-based ECL biosensing, highlighting DNA nanotechnology as both a key modulator of interfacial performance and a core driver of high-sensitivity, high-specificity bioanalytical systems.
Citation: Zhang J, Wang X, Chao J. Recent progress in electrochemiluminescence biosensors based on DNA nanostructures. Life Anal. 2026(2):0012, https://doi.org/10.55092/la20260012.
Life Analysis
Literature review
Not applicable
Recent progress in electrochemiluminescence biosensors based on DNA nanostructures
30-Oct-2026